Recently, the SGLT2 inhibitor NGI001 inhibited diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice [17]. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.